Skip to main content
SpringerLink
Log in

Are HMG-CoA reductase inhibitors cost effective?

  • Drug Economics and Quality of Life
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Goa KL, Barradell LB, McTavish D. Simvastatin: a reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. Pharmacoeconomics 1997 Jan; 11(1): 89–110

    Article  PubMed  CAS  Google Scholar 

  2. O’Brien B. Cholesterol and coronary heart disease: consensus or controversy? 8. Questions of cost-effectiveness. From the Office of Health Economics, London, pp. 78–100

  3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344: 1383–9

    Google Scholar 

  4. Ashraf T, Hay, JW, Pitt B, Wittels E, Crouse J, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 405–414

    Article  Google Scholar 

  5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335(14): 1001–9

    Article  PubMed  CAS  Google Scholar 

  6. Jönsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996; 17: 1001–7

    PubMed  Google Scholar 

  7. Goldman L, Garber AM, Grover SA, et al. Task force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996 Apr; 27: 1020–30

    CAS  Google Scholar 

  8. Reckless JPD. The 4S study and its pharmacoeconomic implications. Pharmacoeconomics 1996 Feb; 9: 101–5

    Article  PubMed  CAS  Google Scholar 

  9. Pedersen TR, Kjekshus J, Berg K, et al. Cholesterol lowering and the use of healthcare resources: results of the Scandinavian Simvastatin Survival Study. Circulation 1996 May 15; 95: 1796–802

    Article  Google Scholar 

  10. Haria M, McTavish, D. Pravastatin: a reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. Drugs 1997; 53(2): 299–336

    Article  PubMed  CAS  Google Scholar 

  11. Aursnes I, Thorvik E, Forsén L. Evaluation of the cost-effectiveness ratio of cholesterol-lowering drugs in secondary prevention of myocardial infarction [abstract]. In: 3rd International Symposium Multiple Risk Factors in Cardiovascular Disease Vascular and Organ Protection. 1994: 26

  12. Goldman L, et al. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991; 265(9): 1141–51

    Article  Google Scholar 

  13. Shepherd J, Cobbe SM, Ford J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301–7

    Article  PubMed  CAS  Google Scholar 

  14. Malik IS, Anderson MH. Cost-efficacy of cholesterol lowering: West of Scotland Coronary Prevention Study versus the Scandinavian Simvastatin Survival Study [abstract]. Heart 1996 May; 75 Suppl. I: 77

    Google Scholar 

  15. Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. Br Med J 1996 Jun 8; 312: 1443–8

    Article  CAS  Google Scholar 

  16. Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia. Drugs 1996 Mar; 51(3): 433–59

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Are HMG-CoA reductase inhibitors cost effective?. Drugs Ther. Perspect 9, 14–16 (1997). https://doi.org/10.2165/00042310-199709090-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199709090-00003

Search

Navigation